Floatz logo

CAFFEINE

CP-B Liver Cirrhosis

Boehringer IngelheimSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the CP-B Liver Cirrhosis cohort.

Asset / SponsorPhaseRating
METOPROLOL
Boehringer Ingelheim
Phase 3BB
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Omeprazole
Boehringer Ingelheim
Phase 2CCC

Same molecule, other indications

CAFFEINE is also rated in:

migraine disorderDormant
BBB
Indicative ·
72 / 100
View asset →
Carcinoma, Renal CellDormant
BB
Indicative ·
70 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →